Organovo Holdings, Inc.

One simple statistic points to the failure of reliance on animal models to predict the human response to novel pharmaceuticals: 95% of drugs fail in human trials despite some measure of efficacy and s

"When I was at Amgen, Inc. , Roger Perlmutter [executive VP and head of R&D] used to say: 'We need to move things forward quickly, because the real experiments are in humans.' " In this podcast, In

The idea of an FXR agonist being the solution for treating metabolic function-associated steatohepatitis (MASH) took a substantial hit when Intercept Pharmaceuticals, Inc. ended development of obeti

“I’m optimistic when it comes to both the integration and the impact of transformative technologies across the life sciences industry,” said Jessica Federer , Bayer ’s former chief digital officer a